Marina Zaretskaya, MD
Neurology · Pittsburgh, PANPI 1386711182
Payments from drug & device makers
Across 350 payments — averaging $143.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Sanofi$4K
- Supernus Pharmaceuticals, Inc.$837
- UCB, Inc.$369
- AstraZeneca$319
- Teva Pharmaceuticals USA, Inc.$282
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$43,62587%
- Food & beverage$6,56113%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $42,714 |
| Sanofi | 13 | $3,777 |
| Supernus Pharmaceuticals, Inc. | 77 | $837 |
| UCB, Inc. | 21 | $369 |
| AstraZeneca | 8 | $319 |
| Teva Pharmaceuticals USA, Inc. | 12 | $282 |
| Amgen(2 entities) | 11 | $215 |
| Mallinckrodt Enterprises LLC | 2 | $142 |
| Neurelis, Inc. | 7 | $137 |
| Novartis | 6 | $131 |
| Lilly USA, LLC | 7 | $130 |
| Argenx US, Inc. | 5 | $130 |
| Adamas Pharmaceuticals, Inc. | 6 | $116 |
| Biogen | 4 | $97 |
| Acadia Pharmaceuticals Inc | 6 | $90 |
| Lundbeck LLC | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 7 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| MDD US Operations, LLC | 3 | $63 |
| SK Life Science, Inc. | 3 | $61 |
| Bristol Myers Squibb | 3 | $56 |
| Pfizer | 2 | $40 |
| EMD Serono, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Livanova USA, Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Upsher-smith Laboratories LLC | 1 | $27 |
| Avion Pharmaceuticals | 2 | $24 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Greenwich Biosciences, Inc. | 1 | $21 |
| Genentech, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$38,950
- QULIPTA$14,872
- ACTHAR$121
- SOLIRIS$121
- DISEASE STATE$110
How this compares
$50,301 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 11 | $45,712 |
| Nurtec OdtRimegepant Sulfate | 27 | $35,475 |
| UbrelvyUbrogepant | 30 | $34,737 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $33,175 |
| Dimethyl Fumarate | 12 | $21,077 |
| Tegretol XrCarbamazepine | 21 | $19,432 |
| Levetiracetam | 553 | $17,729 |
| BotoxOnabotulinumtoxina | 13 | $16,013 |
| Glatiramer Acetate | 11 | $13,841 |
| Carbamazepine ErCarbamazepine | 70 | $13,137 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 171 | $13,023 |
| Emgality PenGalcanezumab-Gnlm | 20 | $12,648 |
| QuliptaAtogepant | 12 | $12,307 |
| NeuproRotigotine | 11 | $11,785 |
| Pyridostigmine Bromide | 80 | $9,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $42,714 | $63,05855 claims |
| Acadia Pharmaceuticals IncNuplazid | $90 | $45,71211 claims |
| PfizerNurtec Odt, Dilantin | $40 | $41,82650 claims |
| UCB, Inc.Neupro | $369 | $11,78511 claims |
| Upsher-smith Laboratories LLCTopiramate | $27 | $1,388110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Pittsburgh
- Jan DrappatzPittsburgh$4M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Valerie SuskiPittsburgh$1.7M
- Oscar LopezPittsburgh$1.5M
- Islam ZaydanPittsburgh$976K
- Amber van LaarPittsburgh$760K
- James ValerianoPittsburgh$714K
- Lana ChahinePittsburgh$633K
- Frank LiebermanPittsburgh$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.